Cencora, Inc. (COR) Stock Score, Valuation & Financial Research
Cencora, Inc. is in the Healthcare sector and Medical - Distribution industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 46/100.
Quick answer for COR
Cencora, Inc. currently has a Wall Street Score of 46/100. The stored market price is $318.5. Its financial score is 41/100. Its valuation score is 51/100. The latest WSS change is +1.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What Cencora, Inc. does
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develop
COR financial snapshot
- Wall Street Score:
- 46/100
- Current price:
- $318.5
- Market capitalization:
- $61.97B
- Revenue:
- $332.77B
- Net income:
- $2.62B
- Free cash flow:
- $3.21B
- Cash:
- $2.82B
- Total debt:
- $11.72B
- EPS:
- 13.52
- P/E ratio:
- 23.6x
- Financial score:
- 41/100
- Valuation score:
- 51/100
- Revenue score:
- 37/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $3.21B, showing positive cash generation.
- The balance sheet shows $2.82B of cash versus $11.72B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +1.4 points: COR increased 1.4 points because Capital improved by 2 points, Valuation improved by 5.5 points.
What the numbers mean
Its current valuation score is 51/100, which Wall Street Score classifies as mixed within the model's valuation framework.
The financial score is 41/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research COR
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.